Doseloop Beta

Antianxiety medications

medication Under review

Antianxiety medications, often called anxiolytics, are a broad group of prescription drugs used to reduce excessive fear, worry, and physiological arousal associated with anxiety disorders. They are not a single supplement or nutrient, but multiple pharmacologic classes that act on different neurotransmitter systems in the brain, including serotonin, norepinephrine, gamma-aminobutyric acid (GABA), and others. The main modern classes include selective serotonin reuptake inhibitors (SSRIs), serotonin–norepinephrine reuptake inhibitors (SNRIs), benzodiazepines, buspirone, certain anticonvulsants, some atypical antidepressants, and a small number of plant-derived or neurosteroid agents. These medications work through several mechanisms. SSRIs and SNRIs increase the availability of serotonin and/or norepinephrine at synapses, gradually dampening excessive anxiety circuitry and improving emotional regulation. Benzodiazepines enhance the effect of GABA, the primary inhibitory neurotransmitter, producing rapid relief of anxiety and muscle tension but also sedation and dependence risk. Buspirone partially stimulates serotonin 5-HT1A receptors with minimal sedation and no classic withdrawal syndrome. Some newer or emerging agents act on melatonin, glutamate, or neurosteroid pathways to modulate stress and fear responses. Clinically, antianxiety medications are used for generalized anxiety disorder, panic disorder, social anxiety disorder, and other anxiety-related conditions, often alongside psychotherapy. In otherwise healthy adults with diagnosed anxiety disorders, these medications can reduce subjective worry, improve functioning, and lessen physical symptoms such as restlessness, insomnia, muscle tension, and autonomic hyperarousal. They are not typically taken by healthy people without an anxiety disorder, but much of the evidence on efficacy and safety comes from adult outpatient samples without major medical comorbidities.

Research summary

AI-Generated Content: This summary was created by AI and may contain errors. Always verify with peer-reviewed sources.

The evidence base for antianxiety medications in adults is extensive, with large numbers of randomized controlled trials and meta-analyses comparing multiple drug classes to placebo and to each other. Across modern agents, SSRIs and SNRIs are generally considered first-line options for chronic anxiety disorders because they show consistent benefits over placebo with acceptable tolerability in large adult samples who are otherwise physically healthy. Benzodiazepines and some older antidepressants are also effective but have higher risks of dependence, withdrawal, cognitive impairment, or other adverse effects, so they are now usually reserved for short-term use or second-line strategies. Network meta-analyses suggest that most active anxiolytic drugs are more effective than placebo in reducing anxiety symptoms, though there is variation in the balance between efficacy and tolerability across agents. Some phytopharmaceutical preparations, such as standardized lavender oil (silexan), have demonstrated clinically meaningful reductions in anxiety with favorable acceptability in adults. Despite the breadth of available medications, there has been limited introduction of entirely new approved anxiolytics in recent decades, and many novel mechanisms under investigation have not yet translated into definitive clinical advantages over existing therapies. Overall, the research consensus supports the use of antianxiety medications as effective tools for adults with clinically significant anxiety, while emphasizing careful selection of agent, dose, and duration to balance benefits against side effects and dependence risk.

Reported Benefits

Reported Side Effects

Related health conditions

Research showing how this habit affects specific health conditions. Always consult healthcare professionals.

May Help With

Research (1 study)

Meta-Analysis

Comparative efficacy and acceptability of anxiolytic drugs for the treatment of anxiety disorders: a systematic review and network meta-analysis.

Psychological Medicine • 2024 • n=28637

He X, Shu L, Guo Y, et al.

Community updates

No updates yet for this supplement.

Be the first to share your experience!

At a glance

Users tracking 0
Linked studies 1
Researched benefits 3
Side effects noted 2